Janus kinase (JAK) inhibitors have become promising treatments for atopic dermatitis (AD),
however no study directly comparing JAK inhibitors with each other has been reported. We …

Given the lack of head‐to‐head studies of systemic therapies in moderate‐to‐severe atopic
dermatitis (AD), network meta‐analyses (NMAs) can provide comparative efficacy and safety …

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis
is made using evaluated clinical criteria. Disease activity and burden are best measured …

Background Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the
IL-31 pathway of itch and skin inflammation in atopic dermatitis. Two international phase 3 …

Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The
objectives of this study were to determine the prevalence of atopic dermatitis in the …

The implementation of treatment guidelines for atopic dermatitis is challenging, in part
because of different guidance documents being used by different groups of specialists and …

Acne, atopic dermatitis (AD), and psoriasis are all chronic dermatologic conditions that
greatly impact the lives of pediatric patients and their caregivers. The visible nature of these …

Introduction Although previously regarded as a children's disease, it is clear that atopic
dermatitis (AD) is also highly prevalent in adults. Because AD is not associated with …

Background Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was
shown to improve the signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) …

Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab
significantly improves clinical outcomes, is well tolerated, and approved to treat …